Filgotinib, an Oral, Selective Janus Kinase 1 Inhibitor, Is Effective in Psoriatic Arthritis Patients with an Inadequate Response to Conventional Disease-Modifying Anti-Rheumatic Drugs: Results from a Randomized, Placebo-Controlled, Phase 2 Study

Mease, PJ, Gladman, DD, van den Bosch, F et al. (10 more authors) (2018) Filgotinib, an Oral, Selective Janus Kinase 1 Inhibitor, Is Effective in Psoriatic Arthritis Patients with an Inadequate Response to Conventional Disease-Modifying Anti-Rheumatic Drugs: Results from a Randomized, Placebo-Controlled, Phase 2 Study. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .

Metadata

Authors/Creators:
  • Mease, PJ
  • Gladman, DD
  • van den Bosch, F
  • Rychlewska-Hanczewska, A
  • Dudek, A
  • Tasset, C
  • Meuleners, L
  • Harrison, P
  • Besuyen, R
  • Kunders, R
  • Mozaffarian, N
  • Coates, LC
  • Helliwell, P
Dates:
  • Published: September 2018
  • Published (online): 15 October 2018
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 15 Nov 2018 16:13
Last Modified: 19 Nov 2018 09:54
Status: Published
Publisher: Wiley
Identification Number: https://doi.org/10.1002/art.40700

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics